Marie-Ange Mouret-Reynier

6PUBLICATIONS
83CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Dec 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Florence Joly, Fernando Bazan, Delphine Garbay

|Aug 06, 2024
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities.

Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra

|Jul 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

Olivia Le Saux, Maude Ardin, Justine Berthet

|Jul 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.

Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler

Pageof 1

Frequent Collaborators

4 joint publications

Frédéric Selle

3 joint publications

Anne-Claire Hardy-Bessard

3 joint publications

Isabelle Ray-Coquard

3 joint publications

Pierre Fournel